VYGR

+ Watchlist + Portfolio

Voyager Therapeutics, Inc.

Regulated industry Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.68
52-Week Range: $2.42 – $5.55
Market Cap: $150.96M
P/E (TTM): —
EPS (TTM): -1.81
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.97
PEG Ratio: —
Return on Equity: -54.09%
Return on Assets: -27.34%
Gross Margin: -236.81%
Operating Margin: -833.87%
Profit Margin: 0.00%
Current Ratio: 7.50
Debt/Equity: 0.21
Total Debt: $32.57M
Free Cash Flow: $-77.31M
Revenue Growth: -39.10%
Earnings Growth: —
Enterprise Value: $67.19M

VYGR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$40.91M	$250.01M	$80.00M	$40.37M
Research & Development	$60.76M	$92.17M	$127.37M	$134.67M
Selling, General & Admin	$30.98M	$35.82M	$35.92M	$37.54M
Operating Expenses	$91.74M	$127.99M	$163.29M	$172.22M
Operating Income	-$50.84M	$122.01M	-$83.29M	-$131.84M
EBITDA	-$44.65M	$126.45M	-$78.56M	-$127.78M
Pretax Income	-$46.39M	$133.74M	-$64.34M	-$119.58M
Income Tax	$16.00K	$1.41M	$665.00K	$144.00K
Net Income	-$46.41M	$132.33M	-$65.00M	-$119.72M
Diluted EPS	-1.21	2.97	-1.13	-2.04
Diluted Shares	38.36M	44.57M	57.67M	58.69M

VYGR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$98.96M	$68.80M	$71.37M	$65.30M
Receivables	$639.00K	$84.45M	$4.49M	$2.92M
Current Assets	$124.50M	$319.68M	$276.81M	$202.69M
Total Assets	$159.36M	$351.28M	$393.05M	$252.28M
Current Liabilities	$72.59M	$64.51M	$49.79M	$26.54M
Total Debt	$23.13M	$20.29M	$43.73M	$36.50M
Total Liabilities	$100.34M	$114.96M	$93.29M	$56.20M
Retained Earnings	-$393.51M	-$261.18M	-$326.18M	-$445.90M
Shareholders' Equity	$59.02M	$236.32M	$299.76M	$196.08M
Working Capital	$51.91M	$255.18M	$227.02M	$176.15M

VYGR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.51M	$77.92M	-$15.31M	-$132.47M
Capital Expenditure	-$2.49M	-$3.26M	-$3.52M	-$2.60M
Free Cash Flow	-$15.00M	$74.66M	-$18.83M	-$135.06M
Depreciation & Amortisation	$6.19M	$4.44M	$4.73M	$4.06M
Stock-Based Compensation	$9.34M	$11.15M	$14.79M	$14.79M
Investing Cash Flow	-$7.34M	-$141.64M	-$94.86M	$125.45M
Financing Cash Flow	$1.11M	$33.65M	$114.02M	$816.00K
Net Change in Cash	-$18.74M	-$30.08M	$3.85M	-$6.21M

VYGR Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$6.47M	$5.20M	$13.37M	$15.34M	$2.59M	$3.17M
Research & Development	$31.53M	$31.33M	$35.87M	$35.95M	$24.60M	$22.04M
Selling, General & Admin	$9.64M	$10.49M	$8.09M	$9.32M	$8.26M	$7.52M
Operating Expenses	$41.17M	$41.83M	$43.96M	$45.27M	$32.86M	$29.56M
Operating Income	-$34.69M	-$36.63M	-$30.59M	-$29.93M	-$30.27M	-$26.39M
EBITDA	-$33.68M	-$35.56M	-$29.66M	-$28.88M	-$29.34M	-$25.48M
Pretax Income	-$30.98M	-$33.37M	-$27.81M	-$27.42M	-$27.92M	-$24.45M
Income Tax	$37.00K	$15.00K	$83.00K	$9.00K	$14.00K	$20.00K
Net Income	-$31.02M	-$33.38M	-$27.89M	-$27.43M	-$27.94M	-$24.47M
Diluted EPS	-0.53	-0.57	-0.47	-0.47	-0.47	-0.40
Diluted Shares	58.35M	58.67M	58.80M	59.70M	59.50M	60.55M

VYGR Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$74.75M	$43.94M	$45.13M	$65.30M	$43.31M	$35.77M
Receivables	$2.11M	—	—	$2.92M	$1.65M	$3.15M
Current Assets	$245.21M	$227.89M	$219.59M	$202.69M	$146.98M	$125.23M
Total Assets	$353.24M	$322.10M	$288.31M	$252.28M	$219.32M	$197.75M
Current Liabilities	$40.21M	$41.98M	$35.49M	$26.54M	$17.45M	$16.68M
Total Debt	$42.00M	$40.20M	$38.37M	$36.50M	$34.57M	$32.57M
Total Liabilities	$80.54M	$78.16M	$68.49M	$56.20M	$45.66M	$43.38M
Retained Earnings	-$357.20M	-$390.59M	-$418.48M	-$445.90M	-$473.84M	-$498.31M
Shareholders' Equity	$272.70M	$244.11M	$219.76M	$196.08M	$173.67M	$154.38M
Working Capital	$204.99M	$185.91M	$184.09M	$176.15M	$129.53M	$108.54M

VYGR Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$37.90M	-$33.26M	-$31.05M	-$30.26M	-$33.42M	-$25.84M
Capital Expenditure	-$658.00K	-$1.10M	-$207.00K	-$626.00K	-$14.00K	—
Free Cash Flow	-$38.55M	-$34.37M	-$31.25M	-$30.89M	-$33.43M	-$25.84M
Depreciation & Amortisation	$1.01M	$1.06M	$932.00K	$1.05M	$932.00K	$908.00K
Stock-Based Compensation	$3.67M	$4.13M	$3.46M	$3.52M	$2.49M	$2.43M
Investing Cash Flow	$41.20M	$1.93M	$34.89M	$47.42M	$8.10M	$15.39M
Financing Cash Flow	$82.00K	$513.00K	$85.00K	$136.00K	$3.33M	$2.91M
Net Change in Cash	$3.39M	-$30.82M	$3.92M	$17.30M	-$21.99M	-$7.54M

Market Snapshot

About

Voyager Therapeutics is a clinical-stage gene therapy company developing treatments for severe neurological diseases. The company focuses on leveraging advanced adeno-associated virus (AAV) capsids and payloads to deliver transformative therapies for conditions including Parkinson disease, Alzheimer disease, and other central nervous system disorders.